Target
FGFRa
57 abstracts
Abstract
Erdafitinib (ERDA) vs ERDA plus cetrelimab (ERDA+CET) for patients (pts) with metastatic urothelial carcinoma (mUC) and fibroblast growth factor receptor alterations (FGFRa): Final results from the phase 2 Norse study.Org: Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St. Bartholomew's Hospital, London, United Kingdom, Department of Urology, Chonnam National University Medical School, Gwangju, South Korea, Janssen Research & Development, Spring House, PA, Gustave Roussy and Paris Saclay University, Villejuif, France, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX,
Abstract
Biomarker analyses in patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial.Org: Memorial Sloan Kettering Cancer Center, University of Bari "A. Moro" and Policlinico Consorziale, Kyushu University, Texas Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea,
Abstract
Irinotecan plus anlotinib or further in combination with penpulimab as second-line treatment of metastatic colorectal cancer (ZL-IRIAN).Org: Shangai,
Abstract
Identification of pharmaceutics with selective activity against melanoma-associated leptomeningeal disease using patient-derived circulating tumor cells.Org: H. Lee Moffitt Cancer Center and Research Institute,
Abstract
Updated results from a phase II study of penpulimab plus anlotinib as first-line therapy in metastatic urothelial cancer (mUC).Org: Medical Ethics Committee of Chinese PLA General Hospital, the First Medical Center of Chinese PLA General Hospital,
Abstract
A phase III randomized trial of eribulin (E) with gemcitabine (G) vs standard of care (SOC) for patients (pts) with metastatic urothelial carcinoma (mUC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937 updated design.Org: Davis Comprehensive Cancer Center, Swog Gu Bladder Patient Advocate,
Abstract
Efficacy and safety of erdafitinib in patients with advanced or metastatic cholangiocarcinoma and FGFR alterations: Pooled analysis of RAGNAR and LUC2001 studies.Org: The People's Liberation Army 81 Hospital, University Hospital Gasthuisberg, Bristol Haematology and Oncology Centre, Statistics & Decision Sciences, Janssen China R&D Center, Chi-Mei Medical Center,
Abstract
First-line regorafenib with nivolumab and FOLFOX or CapeOX in patients with advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: A single-arm, phase Ib/II trial (REGONIVOCTx, EPOC2104).Org: National Cancer Center Hospital East, Kashiwa, Japan, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Chiba, Japan,
Abstract
Anlotinib plus docetaxel in advanced NSCLC progressing on immunotherapy: A pooled analysis of two randomized trials.Org: The Affiliated People’s Hospital of Ningbo University, The First Affiliated Hospital of Hunan College of Traditional Chinese Medicine, First People’s Hospital of Chenzhou, Department of Thoracic Medical Oncology, Zhejiang Cancer Hospital, The Affiliated Cancer Hospital of Xiangya Medical School, Central South University,
Abstract
Anlotinib versus placebo as adjuvant therapy for completely resected high-grade soft tissue sarcomas: Interim results of a phase 2, double-blinded, randomized controlled trial.Org: Centre for Cancer Research & Melbourne Medical School, Dentistry and Health Sciences, Victorian Comprehensive Cancer Centre, Pharmaceutical Sciences,
Abstract
A phase II trial of anlotinib combined chemotherapy as second-line and above therapy in HER2-negative advanced breast cancer.Org: Jiangsu Cancer Hospital, Nanjing Yoko Biomedical, Jiangsu HengRui Medicine, China National Biotec Group, The Affiliated Cancer Hospital of Nanjing Medical University,
Abstract
Real-world study of anlotinib monotherapy and combination therapy for unresectable hepatocellular carcinoma.Org: Department of Infectious Diseases, Guangdong Institute of Hepatology, Guangzhou Medical University,
Abstract
Results of IMPACT 2, a randomized study evaluating molecular profiling and targeted agents in metastatic cancer at MD Anderson Cancer Center.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Investigational Cancer Therapeutics, Department of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan, Division of Cancer Medicine, Department of Diagnostic Radiology, National Cancer Center Hospital, Tokyo, Japan,
Abstract
Alliance EAY191-A6: FOLFOX in combination with binimetinib as second-line therapy for patients with advanced biliary tract cancers (BTCs) with MAPK pathway alterations: A ComboMATCH treatment trial.Org: The Ohio State University Wexner Medical Center and Comprehensive Cancer Center, Trinity Health IHA Medical Group,
Abstract
Efficacy and safety of surufatinib, toripalimab, nab-paclitaxel in combination with radiotherapy or surgery in the first-line treatment of esophageal squamous cell cancer: A single-centered prospective clinical trial.Org: Chinese PLA General Hospital, Beijing InnoCare Pharma Tech, China National Biotec Group,
Abstract
CVM-1118: A potent oral anti-vasculogenic mimicry (VM) agent in combination with nivolumab in patients with unresectable advanced hepatocellular carcinoma (HCC)—A phase IIa study.Org: Department of Surgery, National Cheng Kung University Hospital, Tainan, Taiwan, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, Department of Internal Medicine, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, Division of Hepato-Gastroenterology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan,
Abstract
Phase II study of anlotinib plus durvalumab and chemotherapy as first-line treatment in extensive-stage small cell lung cancer (ES-SCLC): Efficacy and safety analysis.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Respiratory Department of Internal Medicine, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China,
Abstract
Treatment patterns of metastatic urothelial cancer in the United States.Org: Johns Hopkins Greenberg Bladder Cancer Institute,
Abstract
First-line TQB2450 plus anlotinib combined with paclitaxel and cisplatin for advanced esophageal squamous cell carcinoma (ESCC): Update results of a multicenter phase II trial.Org: Department of Medical Oncology, Anyang Cancer Hospital, Anyang, China,
Abstract
Efficacy and safety of regorafenib plus ICIs as second-line treatment in advanced HCC post-frontline treatment failure: A real-world study from a single center.Org: PLA General Hospital,
Abstract
Updated efficacy and safety results from the phase Ib/II study of surufatinib combined with camrelizumab and chemotherapy in patients with advanced colorectal cancer.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Jiangsu Cancer Hospital, Nanjing, China,
Abstract
Meta-analysis of the efficacy and safety of anlotinib combined with chemotherapy in the treatment of small cell lung cancer.Org: Xianyang Central Hospital,
Abstract
Anlotinib combined with penpulimab as first-line treatment for persistent, recurrent, or metastatic cervical cancer: Preliminary results from ALTER-GO-020, a single-arm, open-label, multi-cohort, multi-center phase II clinical study.Org: Shanxi Provincial People’s Hospital, Xi'an, China, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, Sichuan Cancer Hospital & Institute, Sichuan, Cancer Center, Chengdu, China,
Abstract
Tislelizumab in combination with GEMOX and lenvatinib for conversion therapy of unresectable extrahepatic biliary tract carcinoma (eBTC): A prospective, single-arm, phase 2 study.Org: Department of Organ transplantation, the Third Medical Center of Chinese People’s Liberation Army (PLA) General Hospital, Faculty of Hepatopancreatobiliary Surgery, the First Medical Center of Chinese People’s Liberation Army (PLA) General Hospital,
Abstract
Lenvatinib, gemcitabine, and oxaliplatin for 67 patients with fibrolamellar carcinoma.Org: FibroFighters Foundation, NY Presbyterian, St. George Hospital, Helen DeVos Children’s Hospital,
Abstract
Overall survival (OS) of phase 3 CodeBreaK 300 study of sotorasib plus panitumumab (soto+pani) versus investigator’s choice of therapy for KRAS G12C-mutated metastatic colorectal cancer (mCRC).Org: Global Biostatistical Science, Global Development,
Abstract
Efficacy and safety of futibatinib for refractory advanced solid malignancies with FGFR alterations identified in circulating tumor DNA: TiFFANY, A GOZILA-affiliated Trial.Org: Munakata Medical Association Hospital, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan, Aichi Cancer Center Hospital, National Hospital Organization Osaka National Hospital, National Hospital Organization Shikoku Cancer Center,
Abstract
Ex-vivo analysis of programmed cell death on fibrolamellar carcinoma.Org: Rush University Medical School, FibroFighters Foundation, Nagourney Cancer Institute, FibroFighters.org, Rush University Medical Center,
Abstract
Advancing individualized care in advanced gastroesophageal cancers (GEC): A quality improvement initiative.Org: Massachusetts General Hospital, PRIME Education LLC,
Abstract
Dosage optimization in drug development: An FDA Project Optimus analysis of postmarketing requirements issued to repair the cracks.Org: Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Oncology Center of Excellence,
Abstract
Uncovering mechanisms of response of pembrolizumab and lenvatinib for the treatment of platinum-resistant high grade serous ovarian cancer.Org: University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, University of Houston, University of Texas - M. D. Anderson Cancer Center,
Abstract
Geographical and baseline clinical characteristics of participants enrolled in hepatocellular carcinoma (HCC) trials: Analysis of US FDA approvals.Org: FDA/CDER, U.S. Food and Drug Administration, US Food and Drug Administration, Oncology Center of Excellence, Office of New Drugs,
Abstract
A phase III randomized trial of eribulin (E) with or without gemcitabine vs standard of care (SOC) for metastatic urothelial carcinoma (UC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937.Org: SWOG Statistics and Data Management Center, Seattle, WA, University of California Davis Comprehensive Cancer Center, Fred Hutchinson Cancer Research Center, SWOG Cancer Research Network, Baylor College of Medicine,
Abstract
Efficacy and safety of anlotinib combined with anthracycline and ifosfamide followed by anlotinib maintenance in advanced soft tissue sarcoma: A single-arm, phase 2 trial.Org: Rare Tumors Department, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Huaiyin District Jinan, China, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong First Medical University and Shandong Academy of Medical Sciences, Huaiyin District Jinan, Jinan,
Abstract
A prospective, single-arm, single-center, exploratory clinical study of anlotinib combined with irinotecan in second-line and above treatment of HER-2–negative advanced breast cancer.Org: Affiliated Hospital of Jiangnan University (Wuxi Fourth People's Hospital), Wuxi No.2 People’s Hospital, Jiangnan University Affiliated Hospital,
Abstract
Anlotinib combined with sintilimab as first-line treatment in patients with advanced non-clear cell renal cell carcinoma: Preliminary results from an exploratory prospective clinical study.Org: Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China, Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou, China,
Abstract
Clinical efficacy and safety of immune checkpoint inhibitor in combination with regorafenib therapy as second⁃line regimen for patients with unresectable hepatocellular carcinoma.Org: Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China, Shandong Cancer Hospital and Institute, Jinan, shandong, China, Shandong Cancer Hospital and Institute, Jinan, China,
Abstract
Generalizable FGFR prediction across tumor types using self supervised learning.Org: Janssen R & D, LLC, Los Angeles, CA, Janssen R&D, Janssen Research & Development,
Abstract
Efficacy and safety of regorafenib alone or in combinations in the second-line setting for advanced hepatocellular carcinoma: A multicenter real-world study.Org: Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hospital of Nantong University, Nantong, China, Liver Disease Center, The Affiliated Hospital of Qingdao University, Qingdao, China, Oncology Department, Siyang Hospital, Suqian, China,
Abstract
Phase II clinical trial of camrelizumab combined with famitinib for advanced acral and mucosal melanoma.Org: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital and Institute, Beijing, China, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital & Institute, Beijing, China, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital and Institute, Beijing, China, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital & Institute, Beijing, China, Department of Clinical Research & Development, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China,
Abstract
Efficacy and safety of radiation therapy combined with anti-angiogenic agents and immunotherapy for MSS/pMMR metastatic colorectal cancer: A real-world study.Org: Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, Union Hospital, Tongji Medical College Huazhong University of Science and Technology, Huazhong University of Science and Technology Union Shenzhen Hospital, Department of Abdominal Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliate Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China,
Abstract
Regorafenib second-line therapy for surgical recurrent hepatocellular carcinoma: An exploration of continuing regorafenib therapy after tumor progression—A single-center retrospective analysis of 90 cases.Org: Liver Disease Center, The Affiliated Hospital of Qingdao University, Qingdao, China, Department of Interventional medicine,The Affiliated Hospital of Qingdao University, Qingdao, China, Organ Transplantation Center,
Abstract
Immune checkpoint inhibitor plus tyrosine kinase inhibitor with or without transarterial chemoembolization for unresectable hepatocellular carcinoma.Org: The First Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, the Naval Medical University, National Center for Liver Cancer,
Abstract
Efficacy and safety of regorafenib + PD-1 inhibitor combined with local therapy as second-line treatment in patients with advanced hepatocellular carcinoma: A multicenter retrospective real-world study.Org: Sun Yat-sen University Cancer Center, Guangzhou, China,
Abstract
Clinical characteristics and treatment outcome of patients with advanced non-small-cell lung cancer (NSCLC) and FGFR fusions.Org: University of Cologne, University Hospital Cologne Center for Integrated Oncology, Institute for Pathology, Department of Translational Genomics, Network Genomic Medicine,
Abstract
Efficacy and safety analysis of immune checkpoint inhibitors plus angiogenesis inhibitors for treatment of advanced driver-negative NSCLC in elderly patients: A retrospective study.Org: The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Kintor Pharmaceutical, China National Biotec Group,
Abstract
The impact of next generation sequencing on the management of urothelial cell carcinoma.Org: Long Island Jewish Forest Hills, Forest Hills Lab, Long Island Jewish Medical Center, Queens, NY, Northwell Health, New Hyde Park, NY,
Abstract
Identification of clinically actionable biomarkers in an Indian cancer cohort using comprehensive genomic profiling (CGP): An institutional experience.Org: Triesta Sciences, HCG Cancer Center Mumbai, Strand Life Sciences,
Abstract
The combination therapy of anlotinib and penpulimab for the treatment of small cell lung cancer after platinum-based chemotherapy: Results of a phase II exploratory study.Org: Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, China, Changsha, Fuzhou Pulmonary Hospital Fujian, Fuzhou University, Xiangtan Central Hospital,
Abstract
Treatment patterns post atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: Real-world analysis at Veterans Health Administration comparing lenvatinib vs. sorafenib.Org: Univeristy of Texas Health Science Center San Antonio, San Antonio, TX, University of Texas Health Science Center at San Antonio, San Anonio, TX, The University of Texas Health Science Center-San Antonio,
Abstract
Chemotherapy combined with anlotinib, toripalimab and stereotactic radiotherapy in oligo-metastatic nasopharyngeal carcinoma: A prospective, multicenter phase II clinical study.Org: Department of Radiation Oncology, the First Affiliated Hospital of Guangxi Medical University, Nanning, China, Department of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China, Department of Radiation Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China, Department of Oncology, Affiliated Hospital of North Sichuan Medical College, Nanchong, China, Liuzhou Worker's Hospital, Liuzhou, China,
Abstract
Analysis of the efficacy and safety of PD-1/PD-L1 inhibitors–based treatment in myxofibrosarcoma: A single-institution retrospective analysis.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Zhongshan Hospital of Fudan University, Shanghai, China, Fudan University (Xiamen Branch), Shanghai, China, Gracell Biotechnologies, Ltd.,
Abstract
Penpulimab plus platinum-based chemotherapy combined with anlotinib in first-line treatment for persistent, recurrent, or metastatic cervical cancer: A single-arm, open-label phase Ⅱ study (ALTN-AK105-II-06).Org: Department of Gynecology, Puyang Oilfield General Hospital, Puyang, China, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China,
Abstract
A real-world study of TACE combined with regorafenib as a second-line treatment for advanced hepatocellular carcinoma.Org: Peking University Cancer Hospital and Institute (Beijing Cancer Hospital), Beijing, China, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing),
Abstract
Camrelizumab combined with lenvatinib and RALOX-HAIC for hepatocellular carcinoma (HCC) in BCLC stage B and C: A prospective, single-arm, phase II trial (Cal Era study).Org: Hepatology Unit and Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China, Nanfang Hospital, Southern Medical University, Guangzhou, China, Hepatology Unit and Department of Infectious Diseases, Nanfang Hospital Southern Medical University, Guangzhou, China, Department of Infectious Diseases, State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Nanfang Hospital, Southern Medical University, Guangzhou, China,
Abstract
Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Results from a multi-cohort, multicenter phase II trial (ALTER-G-001).Org: Ruijin Hospital, Shanghai Jiaotong University School, Shanghai, China, Shanghai Jiao Tong University School of Medicine, Jiading Central Hospital, Affiliated Hospital of Jiangnan University (Wuxi Fourth People's Hospital), Wuxi Branch of Ruijin Hospital,
Abstract
Update on real-world efficacy of anlotinib in non-small cell lung cancer.Org: The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China, Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, Baotou Tumor Hospital, Baotou, China, Peking University Third Hospital, Beijing, China, Harbin Medical Cancer Hospital, Harbin, China,